<?xml version="1.0" encoding="UTF-8"?>
<fig fig-type="Figure" xml:lang="en" id="bjh15459-fig-0002" orientation="portrait" position="float">
 <label>Figure 2</label>
 <caption>
  <p>Forest plots of the primary analysis results. For the intensive pathway (A) and non‚Äêintensive pathway (B) the models were adjusted for the baseline value of the subscale, the bisphosphonate allocation, International Staging System (
   <styled-content style="fixed-case">ISS</styled-content>), age, sex and the stratification factors of the first randomisation. For the maintenance phase (C), the models were adjusted for the baseline value of the subscale, the treatment group allocated by the first randomisation, 
   <styled-content style="fixed-case">ISS</styled-content>, age and sex. Note that Pain and Fatigue are worse with higher scores whereas Global Health Status/Quality of Life and Physical Functioning are better with higher scores. The black squares and horizontal lines represent the treatment estimate and the associated 95% confidence interval, respectively. 
   <styled-content style="fixed-case">CTD</styled-content>, cyclophosphamide, thalidomide and dexamethasone; 
   <styled-content style="fixed-case">CTD</styled-content>a, attenuated cyclophosphamide, thalidomide and dexamethasone; 
   <styled-content style="fixed-case">CVAD</styled-content>, cyclophosphamide, vincristine, doxorubicin and dexamethasone; 
   <styled-content style="fixed-case">GHS</styled-content>/QoL, Global Health Status/Quality of Life; MP, melphalan and prednisolone.
  </p>
 </caption>
 <graphic id="nlm-graphic-3" xlink:href="BJH-182-816-g002" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
